Lifeline Biotechnologies, Inc. (Lifeline Biotechnologies), has filed four additional patents on its First Warning System methods and technology. The First Warning System has been designed, developed and tested, a process that assists in identifying abnormalities of the breast.
Jim Holmes, Lifeline’s chief executive officer, said that: “We are extending patent protection on our proprietary neural net diagnostic technologies with the filing of three additional patent applications in the United States. These filings relate to four essential elements in its system for analyzing temperature readings of breast tissue to identify cancerous tissue. The patents address the First Warning System’s method for the placement of temperature sensors to obtain reliable temperature readings, its method for analyzing the temperature readings, and its placeholder for assuring proper sensor placement. In addition, a fourth application was filed under the Patent Cooperation Treaty (PCT) to extend Lifeline Biotechnologies’ protection, internationally, on all of the existing patent filings and existing intellectual property including these new filings.”
Lifeline Biotechnologies previously received two patents on its First Warning System hardware and has in the past year filed for a patent on the technological advancements of the First Warning System software. The software has achieved the robust capability of identifying and classifying tissue abnormalities of the breast with sensitivities (ability to identify) of 95% to 100% and specificities (verify) of 87% to 90%. Currently, it is widely recognized that mammograms miss an estimated 20 to 30% of the breast cancers.